Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC
Status:
Recruiting
Trial end date:
2023-09-15
Target enrollment:
Participant gender:
Summary
This trial is a multi-center, phase III, randomized (1:1) clinical trial. The aim is to
explore the efficacy and safety of Sorafenib combined with transarterial chemoembolization as
adjuvant treatment for resectable advanced hepatocellular carcinoma, compared with Sorafenib
alone. The primary endpoint is recurrence-free survival. This trial planned to recruit 158
patients who received curative hepatic resection with resectable advanced hepatocellular
carcinoma. The patients will be randomized into Sorafenib group and Sorafenib+TACE group as
1:1 ratio.